drugset / Trial / NCT01225640

PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay

NCT01225640 ↗

Phase 2 Completed 59 enrolled Sequella, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

PNU-100480 is being developed for the treatment of both drug resistant and sensitive tuberculosis. This is an efficacy and safety study to characterize the effect of PNU-100480 when given for 14 days to treatment-naive patients with drug-sensitive pulmonary tuberculosis.

Timeline

Start
2011-08
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ethambutol Small molecule 275 mg —
Comparator Isoniazid Small molecule 75 mg —
Comparator Pyrazinamide Small molecule 400 mg —
Comparator Rifampicin Small molecule 150 mg —
Subject Sutezolid Small molecule 600 mg —
Subject Sutezolid Small molecule 1200 mg —

Indications